The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / COVID-19 Vaccination in Patients with Rheumatic Disease

COVID-19 Vaccination in Patients with Rheumatic Disease

January 5, 2022 • By Arthritis & Rheumatology

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Two studies on the physical response of patients with rheumatic diseases to vaccination against SARS-CoV-2 are featured in the January issue of Arthritis & Rheumatology.

You Might Also Like
  • Patients with Rheumatic Disease May Experience Flares after SARS-CoV-2 Vaccination
  • COVID-19 Vaccination Induces T Cell Response in Patients Treated with Rituximab
  • COVID-19 Vaccination Strategies Suggested for Patients on Anti-Rheumatic Immunosuppressive Therapy

First, B cell depletion is an established therapeutic principle in a wide range of autoimmune diseases. However, B cells are also critical for inducing protective immunity after infection and vaccination. Thus, Simon et al. undertook a study to assess humoral and cellular immune responses after infection with, or vaccination against, SARS-CoV-2 in patients with B cell depletion and controls who are B cell competent.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In the second study, Connolly et al. evaluated disease flare and post-vaccination reactions (reactogenicity) in patients with rheumatic and musculoskeletal diseases (RMDs) following two-dose SARS-CoV-2 messenger RNA (mRNA) vaccination.

The Studies

Simon et al. assessed antibody responses (tested using enzyme-linked immunosorbent assay) and T cell responses (tested using interferon-γ enzyme-linked immunospot assay) against the SARS-CoV-2 spike S1 and nucleocapsid proteins in a limited number of previously infected (n=6) and vaccinated (n=8) patients with autoimmune diseases and B cell depletion, as well as previously infected (n=30) and vaccinated (n=30) healthy controls.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The researchers observed B cell and T cell responses to the nucleocapsid protein only after infection; however, B cell and T cell responses to spike S1 were found after both infection and vaccination. Vaccination induced a SARS-CoV-2 antibody response in all vaccinated controls (30 of 30 [100%]), but in none of the vaccinated patients with B cell depletion (0 of 8). In contrast, after SARS-CoV-2 infection, both the patients with B cell depletion and healthy controls developed antibodies. T cell responses against the spike S1 and nucleocapsid proteins were found in both infected and vaccinated patients with B cell depletion, as well as in the control group.

These data show that B cell depletion completely blocks humoral but not T cell SARS-CoV-2 vaccination response. Further, limited humoral immune responses are found after SARS-CoV-2 infection in patients with B cell depletion.

Connolly et al. studied patients with rheumatic and musculoskeletal diseases (RMD) who received a two-dose SARS-CoV-2 mRNA vaccination between December 2020 and April  2021. The patients (n=1,377) completed questionnaires detailing local and systemic reactions experienced within seven days of each vaccine dose (dose 1 and dose 2), and one month after dose 2, detailing any flares of their RMD. Associations between demographic/clinical characteristics and flares requiring treatment were evaluated using modified Poisson regression.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Among the patients, 11% reported flares requiring treatment; there were no reports of severe flares. Flares were associated with prior SARS-CoV-2 infection (relative risk [RR] 2.09, P=0.02), flares in the six months preceding vaccination (RR 2.36, P<0.001), and the use of combination immunomodulatory therapy (RR 1.95, P<0.001). The most frequently reported local and systemic reactions included injection site pain (87% after dose 1, 86% after dose 2) and fatigue (60% after dose 1, 80% after dose 2). Reactogenicity increased after dose 2, particularly for systemic reactions. No allergic reactions or SARS-CoV-2 diagnoses were reported.

Pages: 1 2 | Single Page

Filed Under: Conditions Tagged With: Arthritis & Rheumatology, COVID-19, flare, musculoskeletal disease, Rheumatic Disease, SARS-CoV-2, vaccination

You Might Also Like:
  • Patients with Rheumatic Disease May Experience Flares after SARS-CoV-2 Vaccination
  • COVID-19 Vaccination Induces T Cell Response in Patients Treated with Rituximab
  • COVID-19 Vaccination Strategies Suggested for Patients on Anti-Rheumatic Immunosuppressive Therapy
  • COVID-19 Vaccination in Patients with Rheumatic Disease

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)